STEP 6 - REFERENCES

1. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Blade, British Journal of Haematology, 1998, 102, 1115–1123
2. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial.  Moreau BLOOD 17 March 2011 vol. 117 Number 11
3. Criteria for evaluating disease response & progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Samson 1998 Br. Journal of Hematology
4. Magnitude of Response with Myeloma Frontline Therapy Does not predict outcome: Importance of Time to Progression in Southwest Oncology Group Chemotherapy Trials Durie J Clin Onco 22  1857-1863
5. International Response Criteria: IMWG Guidelines. Leukemia, Durie 2006: 20 1467-1473
6. The Importance of bone marrow examination in determining complete response to therapy in patients with MM.  Chee BLOOD 2009 114: 2617-2618
7. Criteria for diagnosis, staging, risk stratification and response assessment of Multiple Myeloma. Kyle Leukemia 2009 January ; 23(1) 3-9 doi: 10.1038/Leu 2008.291
8. Superior outcomes associated with complete response in newly diagnosed MM patients treated with non-intensive therapy; analysis of the phase 3 VISTA study of BORTEZOMIB plus melphalan-prednisone versus melphalan prednisome. Harousseau, BLOOD 2010 116: 3743-3750 doi: 10.1182/blood-2010-03-275800
9. The role of complete response in multiple myeloma. Harousseau, BLOOD 2009 114: 3139-3146
10. Early Response predicts outcome. Palumbo 2010 115: 2332-2333 doi 10:1182/blood-2010-02-268730
11. Better quality of response to lenalidomide plus dexamethasome is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma.  Harousseau, Haematologica 95(10) 1738-1744
12. Toward Deeper Response in MM Blade 2011 BLOOD 117:2986-2987 doi: 10. 1182/blood-2011-02-332536
13. Complete response correlates with long-term progression free and overall survival in elderly myeloma treated with novel agents. Analysis of 1175 patients. Gay 2011 BLOOD 117:3825-2031 doi 10 1182/blood-2010-09.  307645